-
EP4069273
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4069273
| EP4069273 - PEPTIDE COMPOSITIONS AND METHODS FOR TREATING TAUOPATHIES [Right-click to bookmark this link] | Status | Examination is in progress Status updated on 29.09.2023 Database last updated on 14.11.2024 | |
| Former | Request for examination was made Status updated on 09.09.2022 | ||
| Former | The international publication has been made Status updated on 11.06.2021 | ||
| Former | unknown Status updated on 09.12.2020 | Most recent event Tooltip | 13.11.2024 | New entry: Renewal fee paid | Applicant(s) | For all designated states Axoltis Pharma 15-17 rue du Pré de la Reine 63100 Clermont-Ferrand / FR | [2022/41] | Inventor(s) | 01 /
BLANC, Manuel c/o Axoltis Pharma Bioparc 60 Avenue Rockefeller 69008 LYON / FR | 02 /
GODFRIN, Yann c/o Godrin-Lifesciences 8 Impasse de la Source 69300 CALUIRE / FR | 03 /
LE DOUCE, Juliette C/O Axoltis Pharma Bioparc 60 avenue Rockefeller 69008 LYON / FR | [2022/41] | Representative(s) | Lavoix 62, rue de Bonnel 69448 Lyon Cedex 03 / FR | [2022/41] | Application number, filing date | 20816516.7 | 04.12.2020 | [2022/41] | WO2020EP84746 | Priority number, date | EP20190306582 | 05.12.2019 Original published format: EP 19306582 | EP20200305925 | 12.08.2020 Original published format: EP 20305925 | [2022/41] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2021110976 | Date: | 10.06.2021 | Language: | EN | [2021/23] | Type: | A1 Application with search report | No.: | EP4069273 | Date: | 12.10.2022 | Language: | EN | The application published by WIPO in one of the EPO official languages on 10.06.2021 takes the place of the publication of the European patent application. | [2022/41] | Search report(s) | International search report - published on: | EP | 10.06.2021 | Classification | IPC: | A61K38/10, A61P25/28 | [2022/41] | CPC: |
A61K38/39 (EP,IL);
C07K7/08 (KR,US);
A61K38/00 (KR);
A61K9/0019 (US);
A61P25/28 (EP,IL,KR,US);
C07K14/47 (KR)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2022/41] | Title | German: | PEPTIDZUSAMMENSETZUNGEN UND VERFAHREN ZUR BEHANDLUNG VON TAUOPATHIEN | [2022/41] | English: | PEPTIDE COMPOSITIONS AND METHODS FOR TREATING TAUOPATHIES | [2022/41] | French: | COMPOSITIONS PEPTIDIQUES ET MÉTHODES DE TRAITEMENT DES TAUOPATHIES | [2022/41] | Entry into regional phase | 01.06.2022 | National basic fee paid | 01.06.2022 | Designation fee(s) paid | 01.06.2022 | Examination fee paid | Examination procedure | 01.06.2022 | Amendment by applicant (claims and/or description) | 01.06.2022 | Examination requested [2022/41] | 01.06.2022 | Date on which the examining division has become responsible | 29.09.2023 | Despatch of a communication from the examining division (Time limit: M06) | 30.04.2024 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time | 24.06.2024 | Reply to a communication from the examining division | Request for further processing for: | The application is deemed to be withdrawn due to failure to reply to the examination report | 24.06.2024 | Request for further processing filed | 24.06.2024 | Full payment received (date of receipt of payment) Request granted | 28.06.2024 | Decision despatched | Fees paid | Renewal fee | 09.11.2022 | Renewal fee patent year 03 | 09.11.2023 | Renewal fee patent year 04 | 13.11.2024 | Renewal fee patent year 05 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [XY]WO9903890 (UNIV CLERMONT AUVERGNE [FR], et al) [X] 1-10,16 * abstract * * pages 4,5,6 * * claim 6; sequence 8 * [Y] 1-16; | [Y]WO2014028777 (IPIERIAN INC [US]) [Y] 12-15* the whole document *; | [XY]US2018265549 (BRIDON DOMINIQUE [US], et al) [X] 1-11,16 * abstract * * paragraphs [0054] , [0120] , [0121] * * example 1; sequence 2 * * claim 9 * [Y] 1-16 | by applicant | WO9903890 | US6995140 | WO2017051135 | WO2018146283 | - CARSTEN HENNEGES et al., Journal of Alzheimer's Disease, (20160000), vol. 52, pages 1065 - 1080 | - BART SHEEHAN, Therapeutic Advances in Neurological Disorders, (20120000), vol. 5, no. 6, pages 349 - 358 | - Biophysical Journal, (20081100), vol. 95, pages 4879 - 4889 | - MAURICE TLOCKHART BPPRIVAT A., "Amnesia induced in mice by centrally administered β- amyloid peptides involves cholinergic dysfunction", Brain Res, (19960115), vol. 706, no. 2, doi:10.1016/0006-8993(95)01032-7, pages 181 - 93, XP022255566 DOI: http://dx.doi.org/10.1016/0006-8993(95)01032-7 | - MAURICE TSU TPPRIVAT A., "Sigma1 (a1) receptor agonists and neurosteroids attenuate P25-35-amyloid peptide-induced amnesia in mice through a common mechanism", Neuroscience, (19980300), vol. 83, no. 2, doi:10.1016/S0306-4522(97)00405-3, pages 413 - 28, XP025993098 DOI: http://dx.doi.org/10.1016/S0306-4522(97)00405-3 | - MAURICE TMUSTAFA MHDESRUMAUX CKELLER ENAERT GDE LA C GARCFA-BARCELO MRODRIGUEZ CRUZ YGARCIA RODRIGUEZ JC, "Intranasal formulation of erythropoietin (EPO) showed potent protective activity against amyloid toxicity in the A(325-35 non-transgenic mouse model of Alzheimer's disease", J Psychopharmacol, (20131100), vol. 27, no. 11, doi:10.1177/0269881113494939, pages 1044 - 57, XP009500979 DOI: http://dx.doi.org/10.1177/0269881113494939 | - JACKSON SHAM RJWILKINSON D., "The safety and tolerability of donepezil in patients with Alzheimer's Disease", Br J Clin Pharmacol, (20041100), vol. 58, pages 1 - 8, XP055120544 | - MEUNIER JLENI JMAURICE T., "The anti-amnesic and neuroprotective effects of donepezil against amyloid (325-35 peptide-induced toxicity in mice involve an interaction with the a1 receptor", Br J Pharmacol, (20061200), vol. 149, no. 8, pages 998 - 1012 | - HOMMA AIMAI YTAGO HASADA TSHIGETA MIWAMOTO TTAKITA MARIMOTO IKOMA HTAKASE T, "Long-Term Safety and Efficacy of Donepezil in Patients with Severe Alzheimer's Disease", Dement Geriatr Cogn Disord, (20090000), vol. 27, no. 3, pages 232 - 9 |